Article
The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Hematology (Amsterdam, Netherlands) - 1 Dec 2021
Zheng Wen-Shuai, Hu Ya-Lei, Guan Li-Xun, Peng Bo, Wang Shen-Yu
Abstract excerpt
BACKGROUND: Intermediate-risk acute myeloid leukemia (IR-AML) without FLT3-ITD, NPM1 and biallelic CEBPA mutations (here referred to as NPM1mut-negCEBPAdm-negFLT3-ITDneg AML) is a clinically heterogeneous disease. The optimal post-remission therapy (PRT) is unclear for patients with NPM1mut-negCEBPAdm-negFLT3-ITDneg AML who achieved first complete response (CR1). This study aims to explore clinical and molecular...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.